

SUPPLEMENTARY TABLE 1. Comparison by gender as a function of CKD-T stages. Mean and standard deviation or median and interquartile range as appropriate.

	CKD-T STAGE I/II (94 M; 42F)	CKD-T STAGE III (233M;143F)	CKD-T STAGE IV (105M; 93F)	CKD-T STAGE V (5M;12F)	P (Males vs Females at each Stage)
Age (yrs)					
Males	50 (146)	56 (13)	58 (13)	46 (12)	0.2; 0.5; 0.6; 0.08
Females	53 (10)	55 (13)	57 (13)	56 (9)	
Time on dialysis (months)					
Males	20 (11-42)	23 (12-40)	25 (14-39)	18 (8-36)	0.9; 0.1; 0.07; 0.3
Females	23 (10-38)	20 (10-37)	18 (11-37)	32 (15-139)	
Time since Transplantation (months)					
Males	64 (30)	68 (31)	74 (31)	95 (23)	0.9; 0.3; 0.6; 0.007
Females	64 (30)	71 (33)	76 (30)	53 (26)	
History of Cardiovascular Disease					
Males vs Females	15% vs 14%	25% vs 18%	22% vs 15%	60% vs 0%	1; 0.1; 0.3; 0.02

BMI (Kg/m ²)					
Males	26 (4)	27 (4)	27 (4)	25 (3)	0.2; 0.5; 0.1; 0.5
Females	25 (4)	26 (5)	28 (6)	24 (2)	
Pretransplant DM or NODAT (%)					
Males vs Females	26% vs 24%	27% vs 20%	26% vs 32%	0% vs 17%	1; 0.1; 0.4; 1
Parathyroidectomy (%)					
Pretransplant: Males vs Females	3% vs 5%	4% vs 8%	4% vs 6%	0% vs 27%	0.7; 0.2; 0.7; 0.5
Post-transplant: Males vs Females	1% vs 0%	1% vs 1%	0% vs 1%	0% vs 0%	1; 1; 0.5; 1
Patients on steroids (%)					
Males vs Females	65% vs 52%	74% vs 66%	79% vs 83%	100% vs 100%	0.2; 0.1; 0.6; 1

Current prednisone dose (mg/day)					
Males	3 (0-5)	5 (0-5)	5 (2.5-5)	5 (5-7.5)	0.08; 0.03; 0.8; 0.8
Females	2.5 (0-5)	4 (0-5)	5 (2.5-5)	5 (5-5)	
Tacrolimus: Males vs Females	82% vs 71%	67% vs 76%	72 vs 66%	80% vs 75%	0.2; 0.03; 0.4; 1
CsA: Males vs Females	7% vs 14%	16% vs 11%	15% vs 14%	20% vs 8%	0.2; 0.2; 0.8; 0.5
mTORi: Males vs Females (%)	15% vs 15%	20% vs 12%	11% vs 21%	0% vs 25%	0.2; 0.06; 0.05; 0.5
Patients on MMF (%)					
Males vs Females	83% vs 93%	85% vs 87%	82% vs 81%	10% vs 42%	0.2; 0.7; 0.5; 0.04
Acute Rejection (%)					
Males vs Females	11% vs 5%	21% vs 17%	23% vs 30%	40% vs 46%	0.3; 0.3; 0.3; 1
MDRD (ml/mn/1.73 m ²)					
Males	76 (12)	43 (8)	24 (4)	12 (1)	0.2; 0.6; 0.6; 0.5
Females	74 (13)	43 (9)	24 (4)	13 (3)	

Patients on Oral Calcium (as a supplement or as a binder) (%) Males vs Females	12% vs 14%	17% vs 25%	28% vs 25%	60% vs 67%	0.8; 0.06; 0.8; 1
Patients on Vitamin D supplements (%) Males vs Females	12% vs 17%	17% vs 23%	24% vs 26%	0% vs 33%	0.4; 0.1; 0.9; 0.3
Patients on Calcitriol Males vs Females (%)	8% vs 10%	17% vs 23%	24% vs 26%	0% vs 33%	0.4; 0.1; 0.9; 0.3
Patients on Paricalcitol: Males vs Females (%)	1% vs 0%	1% vs 2%	8% vs 5%	20% vs 25%	1; 0.4; 0.6; 1
Patients on Calcimimetic (%) Males vs Females	4% vs 17%	7% vs 10%	12% vs 7%	20% vs 17%	0.04; 0.3; 0.2; 1
Patients on Bisphosphonates (%) Males vs Females	4% vs 10%	4% vs 10%	4% vs 11%	20% vs 0%	0.3; 0.01; 0.09; 1
Corrected total Ca (mg/dl) Males	9.4 (0.4)	9.5 (0.5)	9.3 (0.6)	9 (0.8)	0.01; 0.02; 0.3; 0.4
Females	9.7 (0.5)	9.6 (0.5)	9.5 (0.8)	9.4 (0.8)	

Phosphate (mg/dl)					
Males	3.1 (0.6)	3.2 (0.6)	3.8 (0.8)	5.5 (0.7)	0.02; 0.01; 0.1; 0.1
Females	3.3 (0.4)	3.5 (0.7)	3.9 (0.8)	4.7 (0.9)	
Total AP (U/L)					
Males	81 (33)	81 (28)	86 (43)	59 (9)	1; 0.6; 0.05; 0.1
Females	81 (29)	83 (38)	75 (30)	89 (36)	
Bone AP (pg/ml)					
Males	12 (10-15)	12 (9-16)	13 (10-19)	9 (7-16)	0.8; 0.2; 0.03; 0.2
Females	12 (9-18)	13 (9-16)	11 (9-16)	15 (10-19)	
PTH (pg/ml)					
Males	73 (60-110)	110 (75-180)	190 (106-342)	460 (287-741)	0.3; 0.7; 0.5; 0.7
Females	91 (57-127)	109 (68-173)	173 (109-277]	337 (195-613)	
25OHD ₃ (ng/ml)					
Males	19 (14-26)	19 (14-19)	18 (12-23)	12 (7-12)	0.2; 0.01; 0.2; 0.8
Females	16 (12-23)	16 (11-24)	16 (11-21)	11 (8-11)	

1.25 (OH) ₂ D ₃ (pg/ml)					
Males	51 [39-62]	38 [30-54]	28 [21-40]	18 [10-23]	1; 0.4; 0.6; 0.7
Females	51 [36-63]	37 [28-50]	28 [19-36]	18 [12-36]	
History of clinical fractures (%)					
Pretransplant: Males vs Females	1% vs 2%	2% vs 2%	2% vs 3%	20% vs 0%	0.5; 1; 0.7; 0.3
Post-transplant: Males vs Females	1% vs 5%	2% vs 5%	1% vs 7%	20% vs 0%	0.2; 0.2; 0.06; 0.3
Vertebral deformity ≥grade 2 (%)					
Males vs Females	18% vs 3%	19% vs 11%	12% vs 14%	20% vs 11%	0.06; 0.06; 0.8; 1
Abdominal Aortic Calcification score >0 (%)					
Males vs Females	56% vs 58%	69% vs 66%	72% vs 72%	80% vs 80%	1; 0.7; 1; 1
Pulse Pressure (mm Hg)					
Males	52 (12)	58 (15)	61 (16)	72 (18)	0.5; 0.5; 0.4; 0.2
Females	50 (15)	57 (18)	63 (20)	61 (14)	

CKD-T Stages: I >90; II 60-89; III 30-59; IV 15-29; V <15 ml/mn/1.73 m². NODAT: new onset diabetes after transplantation. AP: Alkaline Phosphatase. 25 (OH)D₃: patients not receiving vitamin D supplements (359 males and 221 females).